# Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct06423326/  
OnCo record `nct06423326` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cisplatin, gemcitabine and nab-paclitaxel in pancreatic cancer, run by Emory University, now recruiting.

## Summary

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT06423326 by Emory University, with a registry enrolment figure of 36 participants, started 2024-08-06 and due to reach its primary completion in 2026-12-31. Interventions recorded: Biopsy; Biospecimen Collection; Cisplatin; Computed Tomography; Gemcitabine; Magnetic Resonance Imaging; Nab-paclitaxel; Pancreatic Surgical Procedure. Conditions listed: Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage I Pancreatic Cancer AJCC v8; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8. Primary outcome: Clinical Response Rate to Neoadjuvant Chemotherapy. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed - resectable and borderline resectable pancreatic ductal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06423326
- Phase: 2
- Setting: A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
- Sponsor: Emory University
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT06423326: https://clinicaltrials.gov/study/NCT06423326

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06423326.json